CLAIMS

1. Use of an isolated polypeptide or a nucleic acid encoding the isolated polypeptide, said polypeptide comprising a modified sequence, wherein the modified sequence is at least 95% identical to SEQ ID NO: 1 and has a F to A mutation at a position corresponding to F32 of SEQ ID NO: 1, in the manufacture of a medicament for increasing a level of regulatory T (T_{reg}) cells in the treatment of a T-cell mediated autoimmune disease in a subject in need thereof, wherein the use comprises measuring the level of T_{reg} cells.

2. The use of claim 1, wherein the T cell-mediated autoimmune disease is selected from the group consisting of multiple sclerosis and type I diabetes.

3. The use of any one of claims 1-2, wherein the isolated polypeptide has an ability to bind to DC-SIGN, hFcγRIIA, or hFcγRIIB.

4. The use of claim 3, wherein the isolated polypeptide has an ability to bind to hFcγRIIA or hFcγRIIB at a K_D of $2x10^{-5}$ M or lower (i.e., K_A of 5.0×10^4 M^{-1} or higher).

5. The use of any one of claims 1-4, wherein the modified sequence is (a) substantially free of sialylation or (b) sialylated at a level lower than that of IgG of the subject.

6. The use of any one of claims 1-5, wherein the modified sequence is at least 95% identical to SEQ ID NO: 2.

7. A non-therapeutic method of increasing a level of regulatory T (T_{reg}) cells, comprising administering to a subject an effective amount of an isolated polypeptide or a nucleic acid encoding the isolated polypeptide, said polypeptide comprising a modified sequence, wherein the modified sequence is at least 95% identical to SEQ ID NO: 1 and has a F to A mutation at a position corresponding to F32 of SEQ ID NO: 1.

8. The method of clam 7, further comprising measuring the level of T_{reg} cells.

9. The method of any one of claims 7-8, wherein the isolated polypeptide has an ability to bind to DC-SIGN, hFcγRIIA, or hFcγRIIB.

10. The method of claim 9, wherein the isolated polypeptide has an ability to bind to hFcγRIIA or hFcγRIIB at a KD of 2x10-5M or lower (i.e., KA of 5.0 x 104M-1 or higher).

11. The method of any one of claims 7-10, wherein the modified sequence is (a) substantially free of sialylation or (b) sialylated at a level lower than that of IgG of the subject.

12. The method of any one of claims 7-11, wherein the modified sequence is at least 95% identical to SEQ ID NO: 2.